BERGENBIO ASA: THIRD QUARTER 2020 RESULTS
Bergen, Norway, 17 November 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces its results for the third quarter of 2020. A presentation and live webcast by BerGenBio’s senior management will take place at 10.00 am CET today, please see below for details. Operational Highlights – third quarter of 2020 (including post-period end) Oncology · Primary endpoint met in BERGAMO Phase II Trial investigating bemcentinib in patients with High Risk Myelodysplastic